CClinicalTrials.gg
Sign In
Not yet recruitingNCT05958485Updated Jul 24, 2023

A Close Examination of Patient Experiences in Glioblastoma Multiforme Clinical Research

An observational study in Glioblastoma Multiforme, sponsored by Power Life Sciences Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-24.

Sponsored by Power Life Sciences Inc. · Observational

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

Clinical research can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative.

The goal is to identify the obstacles and challenges that prevent participation in glioblastoma multiforme clinical study, as well as the reasons for withdrawal or discontinuation.

Insights gained from this study will ultimately benefit those with glioblastoma multiforme who may be invited to participate in clinical trial in the years to come.

02

Conditions studied

  • Glioblastoma Multiforme

Browse trials for

Keywords

  • glioblastoma multiforme
03

In context

Glioblastoma

1,919 studies on the registry are indexed under Glioblastoma; 449 are open to participants now.

This study's planned enrollment of 500 is above the median of 60 across 188 observational studies indexed under Glioblastoma.

Browse Glioblastoma studies →

Lead sponsor

Power Life Sciences Inc. is the lead sponsor of 108 studies on the registry; 107 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with glioblastoma multiforme who are actively considering participating in an observational clinical study, but have not yet completed enrollment and randomization.

Inclusion criteria

  • Diagnosis of glioblastoma multiforme
  • No prior treatment for glioblastoma multiforme
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

Exclusion Criteria:

  • Female patients who are currently pregnant or nursing
  • Enrolled in another research study
  • Patients who are currently receiving any other investigational drug.
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Rate of patients who decide to enroll in a glioblastoma multiforme clinical study.

    Time frame: 3 months

  2. Number of glioblastoma multiforme study participants who remain in clinical trial until completion.

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Publications

  • Michaelsen SR, Christensen IJ, Grunnet K, Stockhausen MT, Broholm H, Kosteljanetz M, Poulsen HS. Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. BMC Cancer. 2013 Sep 3;13:402. doi: 10.1186/1471-2407-13-402. PubMed 24004722 ↗
  • Tosoni A, Gatto L, Franceschi E, Di Nunno V, Lodi R, Mura A, Di Battista M, Bartolini S, Brandes AA. Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study. Eur J Cancer. 2021 Mar;145:171-178. doi: 10.1016/j.ejca.2020.12.027. Epub 2021 Jan 22. PubMed 33486440 ↗
  • Ruda R, Bruno F, Pellerino A, Pronello E, Palmiero R, Bertero L, Crasto S, Polo V, Vitaliani R, Trincia E, Interno V, Porta C, Soffietti R. Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy? J Neurooncol. 2022 Nov;160(2):389-402. doi: 10.1007/s11060-022-04155-9. Epub 2022 Oct 30. PubMed 36309895 ↗

Study documents

  • Informed consent form · Jul 14, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05958485
Lead sponsor
Power Life Sciences Inc.
Responsible party
Sponsor
First posted
Jul 24, 2023
Start date
Aug 2024 (estimated)
Primary completion
Aug 2025 (estimated)
Completion
Aug 2026 (estimated)
Last update
Jul 24, 2023

Study contacts

Michael B Gill
Contact
bask@withpower.com
4159004227
Michael B Gill
study director · Power Life Sciences Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Glioblastoma→

Other studies from this sponsor

Power Life Sciences Inc.

Start the discussion